Introduction: Androgen deprivation therapy (ADT) is currently the backbone treatment of
metastatic prostate cancer and is also used in combination with external beam radiotherapy …

Androgen deprivation therapy using gonadotropin-releasing hormone (GnRH) analogues is
standard treatment for intermediate and advanced prostate cancer. GnRH agonist therapy …

Androgen deprivation therapy (ADT) is the foundation of treatment for patients with locally
advanced, recurrent and metastatic prostate cancer, most commonly using luteinizing …

Aims The aim of this study was to determine whether gonadotropin-releasing hormone
(GnRH) antagonists (an emerging class of drugs to suppress testosterone synthesis in the …

Introduction Relugolix is the first oral gonadotrophin-releasing hormone (GnRH) receptor
antagonist. Based on the phase III HERO trial results, relugolix received Food and Drug …

Open Access site reaction, the requirement of monthly administration, and the less profit in
practice. To seek an oral alternative seems very reasonable. Oral medicine is one of the …

Purpose Comparing gonadotrophin-releasing hormone (GnRH) antagonists and agonists as
androgen deprivation therapy for advanced prostate cancer (PC). Methods This article stems …

Objectives To evaluate efficacy and safety of gonadotropin-releasing hormone (GnRH)
antagonists compared to standard androgen suppression therapy for advanced prostate …

Gonadotropin-releasing hormone (GnRH) receptor agonists are still the most commonly
used androgen deprivation treatment (ADT) drugs for prostate cancer in clinical practice …

Context Androgen deprivation therapy is the mainstay treatment of metastatic prostate
cancer, achieved mainly by gonadotropin-releasing hormone (GnRH) agonists or …